Call for Adoption of Synchronized Biweekly Dosing of Anti-EGFR Agent Cetuximab: Implications for Patients with Metastatic Colorectal Cancer, and Squamous Cell Carcinoma of the Head and Neck

This commentary highlights the article by Parikh and colleagues, regarding biweekly therapy with the anti-EGFR monoclonal antibody, cetuximab, for gastrointestinal cancer.

Detalles Bibliográficos
Autor principal: Kasi, Pashtoon Murtaza
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9074985/
https://www.ncbi.nlm.nih.gov/pubmed/35403691
http://dx.doi.org/10.1093/oncolo/oyac070
_version_ 1784701580473270272
author Kasi, Pashtoon Murtaza
author_facet Kasi, Pashtoon Murtaza
author_sort Kasi, Pashtoon Murtaza
collection PubMed
description This commentary highlights the article by Parikh and colleagues, regarding biweekly therapy with the anti-EGFR monoclonal antibody, cetuximab, for gastrointestinal cancer.
format Online
Article
Text
id pubmed-9074985
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-90749852022-05-09 Call for Adoption of Synchronized Biweekly Dosing of Anti-EGFR Agent Cetuximab: Implications for Patients with Metastatic Colorectal Cancer, and Squamous Cell Carcinoma of the Head and Neck Kasi, Pashtoon Murtaza Oncologist Commentary This commentary highlights the article by Parikh and colleagues, regarding biweekly therapy with the anti-EGFR monoclonal antibody, cetuximab, for gastrointestinal cancer. Oxford University Press 2022-04-11 /pmc/articles/PMC9074985/ /pubmed/35403691 http://dx.doi.org/10.1093/oncolo/oyac070 Text en © The Author(s) 2022. Published by Oxford University Press. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Commentary
Kasi, Pashtoon Murtaza
Call for Adoption of Synchronized Biweekly Dosing of Anti-EGFR Agent Cetuximab: Implications for Patients with Metastatic Colorectal Cancer, and Squamous Cell Carcinoma of the Head and Neck
title Call for Adoption of Synchronized Biweekly Dosing of Anti-EGFR Agent Cetuximab: Implications for Patients with Metastatic Colorectal Cancer, and Squamous Cell Carcinoma of the Head and Neck
title_full Call for Adoption of Synchronized Biweekly Dosing of Anti-EGFR Agent Cetuximab: Implications for Patients with Metastatic Colorectal Cancer, and Squamous Cell Carcinoma of the Head and Neck
title_fullStr Call for Adoption of Synchronized Biweekly Dosing of Anti-EGFR Agent Cetuximab: Implications for Patients with Metastatic Colorectal Cancer, and Squamous Cell Carcinoma of the Head and Neck
title_full_unstemmed Call for Adoption of Synchronized Biweekly Dosing of Anti-EGFR Agent Cetuximab: Implications for Patients with Metastatic Colorectal Cancer, and Squamous Cell Carcinoma of the Head and Neck
title_short Call for Adoption of Synchronized Biweekly Dosing of Anti-EGFR Agent Cetuximab: Implications for Patients with Metastatic Colorectal Cancer, and Squamous Cell Carcinoma of the Head and Neck
title_sort call for adoption of synchronized biweekly dosing of anti-egfr agent cetuximab: implications for patients with metastatic colorectal cancer, and squamous cell carcinoma of the head and neck
topic Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9074985/
https://www.ncbi.nlm.nih.gov/pubmed/35403691
http://dx.doi.org/10.1093/oncolo/oyac070
work_keys_str_mv AT kasipashtoonmurtaza callforadoptionofsynchronizedbiweeklydosingofantiegfragentcetuximabimplicationsforpatientswithmetastaticcolorectalcancerandsquamouscellcarcinomaoftheheadandneck

Ejemplares similares